Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 3 |
List of Tables | 4 | 1 |
List of Figures | 4 | 1 |
Introduction | 5 | 1 |
Global Markets Direct Report Coverage | 5 | 1 |
Vitiligo Overview | 6 | 1 |
Therapeutics Development | 7 | 1 |
Pipeline Products for Vitiligo Overview | 7 | 1 |
Vitiligo Therapeutics under Development by Companies | 8 | 1 |
Vitiligo Pipeline Products Glance | 9 | 2 |
Clinical Stage Products | 9 | 1 |
Early Stage Products | 10 | 1 |
Vitiligo Products under Development by Companies | 11 | 1 |
Vitiligo Companies Involved in Therapeutics Development | 12 | 4 |
Ache Laboratorios Farmaceuticos S/A | 12 | 1 |
Biocon Limited | 13 | 1 |
Bristol-Myers Squibb Company | 14 | 1 |
Clinuvel Pharmaceuticals Limited | 15 | 1 |
Vitiligo Therapeutics Assessment | 16 | 9 |
Assessment by Monotherapy Products | 16 | 1 |
Assessment by Target | 17 | 2 |
Assessment by Mechanism of Action | 19 | 2 |
Assessment by Route of Administration | 21 | 2 |
Assessment by Molecule Type | 23 | 2 |
Drug Profiles | 25 | 17 |
abatacept Drug Profile | 25 | 5 |
ACH-24 Drug Profile | 30 | 1 |
afamelanotide Drug Profile | 31 | 8 |
itolizumab Drug Profile | 39 | 2 |
VLRX-001 Drug Profile | 41 | 1 |
Vitiligo Dormant Projects | 42 | 1 |
Vitiligo Product Development Milestones | 43 | 13 |
Featured News &Press Releases | 43 | 1 |
Dec 03, 2015: Positive preliminary results in Singaporean vitiligo study | 43 | 1 |
Dec 03, 2015: Update on North American vitiligo program for SCENESSE | 44 | 1 |
May 05, 2015: Clinuvel announces innovative melanocortin for new indications | 45 | 1 |
Mar 20, 2015: SCENESSE vitiligo data presented at world s largest dermatology conference | 46 | 1 |
Sep 19, 2014: SCENESSE vitiligo study results published in JAMA Dermatology | 47 | 1 |
May 06, 2014: Clinuvel s Phase II vitiligo study commences in Singapore | 48 | 1 |
Mar 20, 2014: SCENESSE data to feature at American Academy of Dermatology | 48 | 1 |
Nov 04, 2013: Clinuvel to start a Phase II vitiligo study in Singapore | 49 | 1 |
Sep 02, 2013: Five month study follow up shows SCENESSE combination treatment provided stable repigmentation in vitiligo patients | 50 | 1 |
Mar 01, 2013: SCENESSE data to be presented at American Academy of Dermatology, San Gallicano Rare Disease conference | 51 | 1 |
Dec 19, 2012: Clinuvel Pharma Announces Results From Phase IIa Pilot Study Of Scenesse In Vitiligo | 51 | 2 |
Oct 16, 2012: Observations from Clinuvels US vitiligo study published | 53 | 1 |
Mar 15, 2012: Observations from Clinuvels vitiligo and EPP programs being presented at the | 53 | 1 |
Mar 02, 2011: Clinuvel Announces FDA Approval For Vitiligo Drug Trial | 54 | 2 |
Appendix | 56 | 2 |
Methodology | 56 | 1 |
Coverage | 56 | 1 |
Secondary Research | 56 | 1 |
Primary Research | 56 | 1 |
Expert Panel Validation | 56 | 1 |
Contact Us | 56 | 1 |
Disclaimer | 57 | 1 |